Field of the invention

The present invention relates to a method for recovering a protein of interest from a cu ltu re broth by adding a divalent cation and increasing the pH.

Background of the invention

I n the synthesis step of industrial proteins like enzymes, the fermentation step, high titers are achieved. These high protein concentrations can lead to a partial phase transfer from the solu bilized to insolubilized state in the cu ltu re broth. It is possible that the protein is present in form of crystals, precipitates and/or is adsorbed on the solids of the fermentation broth. Partial ly solubilized and insolu bilized protein complicates separation of the protein from the solids in the culture broth and can lead to loss of product. The increase of manufactu ring costs due to loss of product or due to a more complicated separation process determines if product loss is tolerated or product concentration in one phase is increased by additional process steps. Therefore, methods were established to increase the percentage of protein in the liquid or in the solid phase.

Several patent applications are directed to an increased solu bility of enzymes or proteins in the fermentation broth: WO 2004/003187 describes the approach of preventing

crystal lization by addition of polyols, carbohydrates or polyethers. Other patent applications describe methods to increase the percentage of insoluble enzyme and/or to influence crystal morphology to sim plify the fol lowing solid-liquid separation: US 2002/177206 presents a crystal lization process to attain desirable crystal morphology and size. I n this method a starting tem peratu re is selected to attain a desirable crystal morphology and then a tem perature shift is introduced. At this temperature, the crystals continue to grow in desirable fashion with a higher rate of crystal lization and further nucleation is prevented.

US 2011/89344 presents different methods to increase the percentage of insolu ble enzyme in a fermentation broth.

Other patent applications describe how the fermentation broth conditions are changed during solid-liquid separation: I n US 2012/220009 two different broth conditions are applied. First, the protein of interest is retained by a membrane and after a change of conditions broth permeates through the same or another mem brane. The first set of conditions can also cause precipitation or crystal lization. I n other docu ments special apparatuses are used to separate the two solid phases, biomass and solid enzyme: US 7 118 891 describes a method in which a fermentation broth is treated with one or more coagulants and/or one or more floccu lants to form biomass flocks without incorporating the crystal line and/or amorphous metabolites in the flocks. Then the floccu lated biomass is separated from the crystal line and/or amorphous metabolite suspension using a solid liquid separation apparatus li ke a two-phase centrifuge. I n US 6,316,240 enzymes are solubilized before biomass separation by adjusting the pH between 9.5 and 13. WO 2008/110498 describes a method to solu bilize protease crystals or precipitates in fermentation broth by diluting the broth, adding a divalent salt, and adjusting the pH value of the fermentation broth to a pH value below pH 5.5. WO 2017/097869 proposes a method to solu bilize and/or desorb a protein of interest from particulate matters of the fermentation broth by applying one or more wash steps where pH and conductivity of the wash solution are adapted in dependency of the protein’s pi.

However, an al kaline or acidic pH treatment during recovery of the protein may lead to loss of protein activity. Therefore, a novel method for recovering a protein of interest from a fermentation broth is needed which aims at high product yield and preserves the activity of the protei n.

Summary of the invention

The present inventors have fou nd that the addition of a divalent cation to a fermentation broth com prising the protein of interest and adjustment of the pH of the fermentation broth to a pH above 11 leads to a high recovery rate and high remaining activity of the protei n of interest.

Therefore, in a first aspect the invention relates to a method of recovering a protein of interest from a fermentation broth comprising the steps of a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof

com prising the protein of interest, and

b) adjusting the pH of the fermentation broth to more than pH 11, and

c) separating the protein of interest from impu rities and/or biomass.

I n an embodiment, the protein of interest is an enzyme.

The enzyme may be selected from the grou p consisting of amylase, al pha-amylase, glucoamylase, pu l lulanase, protease, metal loprotease, peptidase, lipase, cutinase, acyl transferase, cel lu lase, endoglucanase, glucosidase, cel lu biohyd rolase, xylanase,

xyloglucantransferase, xylosidase, mannanase, phytase, phosphatase, xylose isomerase, glucoase isomerase, lactase, acetolactate decarboxylase, pectinase, pectin methylesterase, polygalactu ronidase, lyase, pectate lyase, arabinase, arabinofu ranosidase, galactanase, a laccase, peroxidase and an asparaginase, preferably wherein the enzyme is an amylase or protease.

I n another embodiment, the divalent cation is selected from the grou p consisting of Ca ²⁺ , Mg ²⁺ , Ba ²⁺ , Pb ²⁺ , Fe ²⁺ , Zn ²⁺ , Ni ²⁺ , Cu ²⁺ , M n ²⁺ , Sr ²⁺ , Co ²⁺ and Be ²⁺ .

I n another embodiment, the salt of the divalent cation is the chloride, nitrate, formate, acetate, phosphate or su lfate salt of the divalent cation. I n an embodiment, step a) and step b) are performed simu ltaneously, or step a) is performed before step b) .

I n an embodiment, the pH is adjusted to a pH of between 11 and 13, preferably wherein the pH may be adjusted by adding NaOH.

I n yet another embodiment, the method fu rther com prises prior to step a) and/or b) the fermentation of a microorganism.

I n another embodiment, the protein of interest is secreted by the microorganism into the fermentation broth. The microorganism may be a bacteriu m. The bacterium may be selected from the grou p consisting of Bacil lus, Streptomyces, Escherichia, Buttiauxel la and

Pseudomonas. Alternatively, the microorganism may be a fungal cel l selected from the phyla Ascomycota, Basidiomycota, Chytridiomycota, Zygomycota, and Oomycota, as wel l as al l mitosporic fu ngi and Saccharomycoideae. Preferably, the fu ngal cel l is selected from the group consisting of Aspergillus, PeniciHium, Candida, Trichoderma, Thermotheiomyces, \n particu lar Thermothelomyces thermophUa, and Pi chi a.

I n an embodiment, the salt of the divalent cation is added to the fermentation broth to obtain a final concentration of 0.01-5 % (w/v) of the salt of the divalent cation in the broth.

I n an embodiment, the fermentation broth prior to the addition of the divalent cation com prises phosphate.

I n a fu rther embodiment, the method fu rther comprises a step (d) of preparing a formu lation containing the protein.

I n a second aspect, the invention relates to a method of stabilizing a protein of interest in a fermentation broth or fraction thereof, said method com prising the steps of a) adding a salt of a divalent cation to the fermentation broth comprising the protein of interest, and

b) adjusting the pH of the fermentation broth to a pH of more than 11.

Brief description of the drawings

Figu re 1: Solubilization of the protein as measu red by absorbance at 700 nm dependent on the pH of the supernatant.

Figu re 2: Amylase activity dependent on the pH of the supernatant.

Figu re 3: Amylase activity dependent on the pH of the supernatant in the presence of 7.5 g/l calciu m ch loride.

Definitions U nless otherwise noted, the terms used herein are to be understood according to

conventional usage by those of ordinary skil l in the relevant art.

As used in this specification and in the appended claims, the singular forms of "a" and "an" also include the respective plu rals un less the context clearly dictates otherwise. I n the context of the present invention, the terms "about" and "approximately" denote an interval of accuracy that a person skil led in the art wil l u nderstand to stil l ensu re the tech nical effect of the feature in question. The term typical ly indicates a deviation from the indicated numerical value of ± 20 %, preferably ± 15 %, more preferably ± 10 %, and even more preferably ± 5 %.

It is to be u nderstood that the term "comprising" is not limiting. For the pu rposes of the present invention the term "consisting of" is considered to be a preferred em bodiment of the term "comprising". If hereinafter a group is defined to com prise at least a certain num ber of embodiments, this is meant to also encom pass a group which preferably consists of these embodiments on ly.

Fu rthermore, the terms "first", "second", "third" or "(a)", "(b)", "(c)", "(d)" etc. and the like in the description and in the claims are used for distinguishing between similar elements and not necessarily for describing a sequential or ch ronological order. It is to be u nderstood that the terms so used are interchangeable u nder appropriate circumstances and that the embodiments of the invention described herein are capable of operation in other sequences than described or il lustrated herein. I n case the terms "first", "second", "third" or "(a)", "(b)", "(c)", "(d)", "i", "ii" etc. relate to steps of a method or use or assay, there is no time or time interval coherence between the steps, i.e. the steps may be carried out simultaneously or there may be time intervals of seconds, minutes, hours, days, weeks, months or even years between such steps, un less otherwise indicated in the application as set forth herein above or below.

It is to be u nderstood that this invention is not limited to the particular methodology, protocols, reagents etc. described herein as these may vary. It is also to be understood that the terminology used herein is for the pu rpose of describing particu lar em bodiments on ly, and is not intended to limit the scope of the present invention that wil l be limited on ly by the appended claims. U nless defined otherwise, al l technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skil l in the art.

Throughout this application, various pu blications are referenced. The disclosures of al l of these pu blications and those references cited within those pu blications in their entireties are hereby incorporated by reference into this application in order to more fu l ly describe the state of the art to which this invention pertains.

A“fermentation process” comprises the cu ltivation of cel ls in a suitable fermentation mediu m. “Cu ltivation of the cel ls” or“growth of the cel ls” is not u nderstood to be limited to an exponential growth phase, but can also include the physiological state of the cel ls at the begin ning of growth after inoculation and du ring a stationary phase.

An industrial ly relevant fermentation process encom passes a fermentation process on a volu me scale which is at least 1 m3 with regard to the nominal fermenter size, preferably at least 5 m3, more preferably at least 10 m3, even more preferably at least 25 m3, most preferably at least 50 m3. Preferably, the industrial ly relevant fermentation process encompasses a fermentation process on a volu me scale which is 1-500 m3 with regard to the nominal fermenter size, pre-ferably 5-500 m3, more preferably 10-500 m3, even more preferably 25-500 m3, most pre-ferably 50-500 m3. I n other words, an industrial ly relevant fermentation process encompasses a fermentation process on a volu me scale which is at least 1000 L with regard to the nominal fermenter size, preferably at least 5,000 L, more preferably at least 10,000 L, even more preferably at least 25,000 L and most preferably at least 50,000 L. Preferably, the industrial ly relevant fermentation process encompasses a fermentation process on a volume scale which is 1000-500,000 L, preferably 5,000-500,000 L, more preferably 10,000-500,000 L, even more preferably 25,000-500,000 L and most preferably 50,000-500,000 L.

The term“fermentation broth” or“cu lture broth” as used herein describes the fermentation medium containing recom binant or non-recom binant cel ls, which are cu ltivated to express the protein of interest. I n some embodiments, the recombinant or non-recombinant cel ls may secrete the protein of interest into the fermentation mediu m.

The term“fraction of the fermentation broth” denotes on ly part of the fermentation broth. Fractions of the fermentation broth may be obtained by centrifugation of the fermentation broth leading to a su pernatant com prising the liquid part and a spin-down fraction com prising the cel ls and other insolu bles. Alternatively, the fractions of the fermentation broth may be obtained by filtration of the fermentation broth leading to a filtrate or permeate com prising the liquid part and a retentate comprising the cel ls and/or other insolu bles. Fractions may also include parts of the fermentation broth, if not the complete fermentation broth present in the fermenter is harvested for the recovery of the protein of interest.

The term“fermentation mediu m” refers to a water-based solution containing one or more chemical compounds that can support the growth of cel ls.

As used in this application, the term "divalent cation" means a cation having a +2 charge. Suitable divalent cations include Ca ²⁺ , Mg ²⁺ , Ba ²⁺ , Pb ²⁺ , Fe ²⁺ , Zn ²⁺ , Ni ²⁺ , Cu ²⁺ , M n ²⁺ , Sr ²⁺ , Co ²⁺ and Be ²⁺ . Preferably, the divalent cation is Ca ²⁺ or Mg ²⁺ . The divalent cation can be in either solid or dissolved form, or both. I n solid form, the cation is ionical ly bonded to an anion thereby making a salt, herein cal led "salt of a divalent cation” or "divalent salt".

“I mpurities” in fermentation broth typical ly include u nconverted sugars, residual salts and by-products. The term“biomass” refers to cel ls which produce the desired product and fragments of these cel ls present in the fermentation broth.

The term“titer of a protein of interest” as used herein is u nderstood as the amou nt of protein of interest in g per volu me of fermentation broth in liter.

The terms "recovering” or“purifying” may be used interchangeably and are intended to mean "rendering more pu re". They refer to a process in which the protein of interest is separated from other com pou nds or cel ls present in the fermentation broth.

The term "heterologous” (or exogenous or foreign or recom binant or non-native) polypeptide is defined herein as a polypeptide that is not native to the host cel l, a polypeptide native to the host cel l in which structu ral modifications, e.g., deletions, su bstitutions, and/or insertions, have been made by recombinant DNA techniques to alter the native polypeptide, or a polypeptide native to the host cel l whose expression is quantitatively altered or whose expression is directed from a genomic location different from the native host cel l as a resu lt of manipu lation of the DNA of the host cel l by recombinant DNA techniques, or whose expression is quantitatively altered as a resu lt of manipu lation of the regu latory elements of the polynucleotide by recombinant DNA tech niques e.g., a stronger promoter; or a polynucleotide native to the host cel l , but integrated not within its natu ral genetic environment as a resu lt of genetic manipulation by recombinant DNA techniques.

With respect to two or more polynucleotide sequences or two or more amino acid sequences, the term "heterologous” is used to characterize that the two or more polynucleotide sequences or two or more amino acid sequences are natu ral ly not occu rring in the specific com bination with each other.

For the pu rposes of the invention, "recombinant" (or transgenic) with regard to a cel l or an organism means that the cel l or organism contains a heterologous polynucleotide which is introduced by man by gene technology and with regard to a polynucleotide includes al l those constructions brought about by man by gene tech nology / recombinant DNA tech niques in which either

(a) the sequence of the polynucleotide or a part thereof, or

(b) one or more genetic control sequences which are operably lin ked with the

polynucleotide, including but not limited thereto a promoter, or

(c) both a) and b) are not located in their wildtype genetic environ ment or have been modified.

The term“native” (or wildtype or endogenous) cell or organism and“native” (or wildtype or endogenous) polynucleotide or polypeptide refers to the cel l or organism as found in natu re and to the polynucleotide or polypeptide in question as fou nd in a cel l in its natu ral form and genetic environment, respectively (i.e., without there being any human intervention) . The term "host cel l", as used herein, includes any cel l type that is susceptible to

transformation, transfection, transduction, conjugation, and the like with a nucleic acid construct or expression vector.

The term "introduction" and variations thereof are defined herein as the transfer of a DNA into a host cel l. The introduction of a DNA into a host cel l can be accomplished by any method known in the art, including, the not limited to, transformation, transfection, transduction, conjugation, and the like.

Detailed description

The present invention may be understood more readily by reference to the fol lowing detailed description of the preferred embodiments of the invention and the examples included herei n.

The inventors su rprisingly found that the activity of a protein, e.g. an enzyme, can be retained or substantial ly retained, if a salt of a divalent cation is added to the fermentation broth before the pH is adjusted to pH values above pH 11.

An increase in pH to a value above 11 mediates the solubilization of the protein of interest which may be present in form of protein crystals, protein precipitates, and/or protein bou nd to the cel l mass or other insoluble material (see Example 1) . The high pH, however, may lead to a loss of protein activity of the protein of interest, e.g. an enzyme. Further, the high pH may lead to instability of the protein of interest, e.g. an enzyme.

Without wishing to be bou nd to a particu lar theory, it is hypothesized that phosphate ions present in the fermentation mediu m tend to extract divalent cations, preferably Ca2+, from the proteins, in particu lar enzymes, and to form insolu ble salts, when the pH of the broth or fraction thereof is increased. By the addition of divalent cations to the fermentation broth before or simu ltaneous to increasing the pH, the phosphate in the mediu m com plexes with these added cations and the cations bou nd to the enzyme wil l not be extracted. Therefore, the enzyme remains stable and soluble with reduced loss in its activity during the incu bation at high pH.

Exam ples of suitable divalent cations that may be added to the fermentation broth include Group HA elements (al kaline earth metals) . Particu larly preferred divalent cations are Ca2+ and Mg2+.

Therefore, the invention relates to a method of recovering a protein of interest from a fermentation broth com prising the steps of a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof

com prising the protein of interest, and

b) adjusting the pH of the fermentation broth to more than pH 11, and c) separating the protein of interest from impu rities and/or biomass.

Fu rthermore, the invention relates to a method of stabilizing a protein of interest in a fermentation broth or fraction thereof, said method com prising the steps of a) adding a salt of a divalent cation to the fermentation broth comprising the protein of interest, and

b) adjusting the pH of the fermentation broth to a pH of more than 11.

The method of the invention may be applied to the fermentation broth or to a fraction of the fermentation broth.

The fraction of the fermentation broth may be obtained by filtration, preferably by microfiltration, or by centrifugation, preferably by decanter centrifugation, disc stack centrifugation or a nozzle separator. A fraction of the fermentation broth may also be obtained by removing a part of the fermentation broth present in the fermenter.

I n a preferred em bodiment, the fraction of the fermentation broth is selected from (i) the spin-down fraction obtained by centrifugation of the fermentation broth, and (ii) the su pernatant obtained by centrifugation of the fermentation broth. Preferably, the

su pernatant is used in the method of the present invention.

I n another preferred em bodiment, the fraction of the fermentation broth may be the filtrate/retentate obtained by filtration of the fermentation broth. The filtration may be dead-end or crossflow filtration.

Fu rther, one or more flocculation agents may be added to the fermentation broth. The floccu lation agent(s) may be added to the fermentation broth before separation of the cel ls. Floccu lation agents are known in the art and are especial ly used to provide a protein solution (e.g. a fermentation broth) which is particularly wel l fitted for centrifugation, filtration or for membrane concentration/filtration. A suitable floccu lation agent may be any solu ble Fe or Al com pou nd. Use of such solu ble Fe and/or Al com pou nds as floccu lation agent(s) are known from WO 96/38469. Any solu ble Fe or Al com pou nd, or any mixture thereof, may be used, such as AI ₂ (S0 ₄ ) ₃ , NaAI0 ₂ , K ₂ AI ₂ 0 ₄ , AI (N0 ₃ ) ₃ , AICI ₃ , Al-acetate, Al- formate, Fe ₂ (S0 ₄ ) ₃ , Fe(l l l) -formate, Fe(l l l) -acetate, Fe(l l) -formate and Fe(l l) -acetate.

Preferably the compound is a polymer alu minum ch lorohyd rate (e.g., PAX-18 available from Kemira) or AI ₂ (S0 ₄ ) ₃ . Further suitable floccu lation agents include organic polymers, such as Su perfloe C-521 and Su perfloe A-130 (available form Kemira) , which are cationic and anionic organic polymers, respectively, of different molecular weights.

I n another embodiment, the method of the present invention does not com prise adding a trivalent or polymeric floccu lation agent to the fermentation broth. I n another em bodiment, the solution containing the salt of the divalent cation which is added in step a) of the method of the present invention does not contain a floccu lating agent. Preferably, the solution containing the salt of the divalent cation which is added in step a) of the method of the present invention does not contain a polymeric floccu lating agent, like Su perfloe C-521 and Su perfloe A-130.

Method step a) adding a salt of a divalent cation

I n an embodiment of the invention, the divalent cation is selected from Ca ²⁺ , Mg ²⁺ , Ba ²⁺ ,

Pb ²⁺ , Fe ²⁺ , Zn ²⁺ , Ni ²⁺ , Cu ²⁺ , M n ²⁺ , Sr ²⁺ , Co ²⁺ , Be ²⁺ and Ra ²⁺ . Preferred divalent cations according to the present invention include G rou p HA elements (al kaline earth metals) , i.e. Ca ²⁺ , Mg ²⁺ , Sr ²⁺ , Ba ²⁺ , Ra ²⁺ , Be ²⁺ . Particu larly preferred divalent cations are Ca ²⁺ and Mg ²⁺ and the most preferred divalent cation is Ca ²⁺ .

I n a fu rther em bodiment of the invention, the salt of the divalent cation is the chloride, phosphate, su lfate, nitrate, formate or acetate salt of the divalent cation such as calcium chloride, calciu m phosphate, calciu m sulfate, calciu m nitrate, calcium acetate, magnesium chloride, magnesium phosphate, magnesium su lfate, magnesium nitrate or magnesiu m acetate. Preferably, the salt of the divalent cation is calciu m ch loride (CaCI ₂ ) or magnesium chloride (MgCI ₂ ) , more preferably, the salt of the divalent cation is CaCI ₂ . I n another embodiment, the salt of the divalent cation is calciu m formate or calciu m acetate or magnesiu m formate or acetate.

I n an em bodiment, the divalent salt is added to the fermentation broth or a fraction thereof in a concentration of 0.01-5%, 0.01-4%, 0.01-3%, 0.01-2% or 0.01-1% of the fermentation broth (w/w) , in particu lar 0.01-1% of the fermentation broth (w/w). Preferably the divalent salt is added to the fermentation broth or a fraction thereof in a concentration of 0.1-1%, more preferably in a concentration of 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95% or 1% of the fermentation broth (w/w) . Most preferably the divalent salt is added to the fermentation broth or a fraction thereof in a concentration of 0.75% of the fermentation broth (w/w) . The divalent salt is typical ly added either in-line, or in a stirred tank, or by any other method known in the art.

I n an em bodiment, the divalent salt is added to the fermentation broth or a fraction thereof in at least stoichiometric amou nts of the divalent cation to phosphate ions. Preferably, the molar ratio between the divalent cation and the phosphate ions is greater than 1, such as between 2 and 10, more preferably between 2 and 5. Hence, the molar ratio between the divalent cation and the phosphate ions is 2, 3, 4, 5, 6, 7, 8, 9, or 10, preferably 2, 3, 4, or 5, most preferably 2 or 3. The divalent salt is typically added either in-line, or in a stirred tank, or by any other method known in the art.

The final amou nt of added divalent cation may depend on the amou nt of phosphate in the fermentation broth present at the end of the fermentation process. As discussed above, it is believed that after increasing the pH the phosphate remaining in the fermentation broth wil l extract divalent cations from the enzymes present in the fermentation broth. This means, the more phosphate present in the fermentation broth prior to protein recovery the higher is the amou nt of divalent cation salt which has to be added to the broth. Phosphate may be added at the begin ning of the fermentation process to the fermentation mediu m and wil l be consu med by the cu ltured microorganism. Depending on the fermentation protocol, additional phosphate may be fed du ring the cultu re. Therefore, the phosphate remaining at the end of the fermentation process depends on the fermentation protocol.

I n a preferred embodiment, the fermentation broth comprises phosphate, when the salt of the divalent cation is added. The amou nt of phosphate present in the fermentation broth can be determined by any means known in the art, e.g. by analytical HPLC. The concentration of phosphate at the end of the fermentation process may be 0-5 g/L, 0-4 g/L, 0-3 g/L, 0-2 g/L or 0-1 g/L. The concentration of phosphate at the end of the fermentation process may be 0.1 -3 g/L or 0.2- 3 g/l or 0.1 -1 g/L or 0.2-1 g/L. Preferably, in the method of the present invention the phosphate concentration in the solution comprising the protein of interest, e.g., the fermentation broth or a fraction thereof, does not exceed 10 mmol after the addition of the salt of the divalent cation.

Preferably, in the method of the present invention the phosphate concentration in the fermentation broth or a fraction thereof does not exceed 10 mmol after the addition of the salt of the divalent cation. Preferably, no phosphate is added to the fermentation broth or a fraction thereof after completion of the fermentation process except by the addition of a phosphate containing salt of the divalent cation. Preferably, no phosphate is added to the fermentation broth or a fraction thereof after completion of the fermentation process. Most preferably, the fermentation broth or a fraction thereof prior to the addition of the divalent cation comprises phosphate in a concentration that does not exceed 10 mmol and no phosphate is added to the fermentation broth or a fraction thereof after completion of the fermentation process.

Method step b) adjusting the pH

According to the invention, simu ltaneously to step a) or after the salt of a divalent cation has been added to the fermentation broth or a fraction thereof, the pH of the fermentation broth is adjusted to a pH value above 11. Preferably the pH is adjusted to a value of at least pH 11.1, at least pH 11.2, at least pH 11.3, at least pH 11.4, or at least pH 11.5, preferably of at least pH 11.5. Preferably the pH is adjusted to a value of between pH 11 and pH 13, e.g. to a pH of 11.2, 11.5, 12.0, 12.5, or 12.7, more preferable to a value between pH 11.0 and pH 12.5, e.g., to a pH of 11.1, 11.2, 11.3, 11.4, 11.5, 11.6, 11.7, 11.8, 11.9, 12.0, 12.1, 12.2, 12.3, or

12.4. Preferably the pH is adjusted to a value of more than pH 11 to at most pH 13.0, e.g. to a pH of 11.2, 11.5, 12.0, 12.2, 12.5, pH 12.7, or pH 13.0, preferably the pH is adjusted to a value of more than pH 11 to at most pH 12.5, e.g. to a pH of 11.2, 11.5, 12.0, 12.2, or 12.5, preferably the pH is adjusted to a value of more than pH 11 to at most pH 12.0, e.g. to a pH of 11.2, 11.5, 11.7, or 12.0. Preferably, the pH is adjusted to pH 11.1 to pH 13, pH 11.1 to pH

12.5, pH 11.1 to pH 12, pH 11.2 to pH 13, pH 11.2 to pH 12.5, pH 11.2 to pH 12, pH 11.5 to pH 13, pH 11.5 to pH 12.5, or pH 11.5 to pH 12. Preferably, the pH of the fermentation broth is adjusted to a pH value above 11.0, such as a pH of 11.2, 11.5, 12, 12.5 or 13, preferably to a pH of more than 11.0 to at most 12.0, such as a pH of 11.1, 11.2, 11.3, 11.4, 11.5, 11.6, 11.7, 11.8, 11.9 or 12.0, after the salt of a divalent cation has been added to the fermentation broth, i.e. step a) is performed before step b).

The pH may be adjusted by using any suitable strategy known to the person skil led in the art. Any suitable base or basic solution may be used to adjust the pH. Preferred bases are sodium hyd roxide, potassiu m hyd roxide and am monium hyd roxide. I n a preferred

embodiment of the invention, the pH is adjusted by adding NaOH.

I n another embodiment of the invention, the method steps of: a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof

com prising the protein of interest, and

b) adjusting the pH of the fermentation broth to more than pH 11 may be performed simu ltaneously or step a) is performed prior to step b) .

Preferably, step a) is performed prior to step b) . Step b) does not have to immediately fol low step a) . Hence, in one embodiment, step b) is performed 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, one hou r, two hou rs or three hours after com pletion of step a) .

If steps a) and b) are performed simultaneously, a continuous and rapid mixing of the fermentation broth, the divalent cation salt and the added base is required so that the protein does not come into contact with high concentrations of the base in the absence of the divalent cation. It is thus recommended to minimize local pH peaks to prevent reduction in protein activity and/or stability by thorough mixing of the fermentation broth, the divalent cation salt and the added base. This may also be achieved by in-line mixing.

I n another embodiment, an additional step may be performed between step a) and step b). The additional step may be the addition of com pou nds such as floccu lation agents, filtration aids/additives, activated charcoal, decolorants and the like.

After adding the divalent salt and adjusting the pH, the fermentation broth is constantly stirred over a predetermined incubation time. The incubation time may vary from 1 to 120 minutes. The incu bation time may be 1 minute, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 60 minutes, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, 110 minutes, or 120 minutes. Preferably, the incubation time is between 60-90 minutes, most preferably, the incu bation time is 60 minutes. If the pH is adjusted by in-line addition of the base, the incu bation time is u p to 10 minutes, preferably u p to 5 minutes, most preferably u p to 1 minute.

Du ring this incu bation time, solu bilization of protein crystals and/or protein precipitates and/or protein bound to cel ls/insolu ble is promoted. Hence, at the end of the incu bation time the protein is present in solu ble form. As mentioned above, the incubation at a high pH leads to the dissolution of crystal lized or precipitated protein (see also Exam ple 1) . However, high pH treatment may have a negative effect on the stability and thus may have detrimental effects on the activity of the protein to be pu rified, e.g. an enzyme. The addition of a divalent cation to the fermentation broth stabilizes the protein of interest and preserves its activity and stability (see Examples 2 and 3) .

By using the method of the present invention, the enzyme substantial ly retains its activity when the pH of the fermentation broth or fraction thereof is increased. The term

"su bstantial ly retains its activity" means that the activity of the enzyme after the pH increase is at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84% or at least 85% of the activity of the enzyme before the pH increase, preferably the activity of the enzyme after the pH increase is at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93% or at least 94% of the activity of the enzyme before the pH increase and more preferably the activity of the enzyme after the pH increase is at least at least 95%, at least 96%, at least 97% or at least 98% of the activity of the enzyme before the pH increase. Methods to determine enzyme activity are discussed below in the context of the enzymes which may be used in the present invention.

"Stabilization of the enzyme" means that the enzyme substantial ly retains its conformation and therefore also its activity as described above.

I n one embodiment, the fermentation broth, or the fraction thereof, may be diluted before or after the method of the invention is performed. The fermentation broth comprising the protein of interest may be diluted 100-2000% (w/w) , preferably 100-1500% (w/w) , more preferably 100-1000% (w/w), in particu lar 200-700% (w/w) . The fermentation broth may be diluted with water.

I n an alternative embodiment, the fermentation broth is not diluted before the method of the invention is performed.

Fermentation process

I n an embodiment, the inventive methods fu rther comprise prior to step a) and b) the fermentation of a host cel l, preferably the fermentation of a microorganism.

The fermentation process may be of any known set-u p, such as a batch process, a fed- batch process or a continuous fermentation process.

A batch fermentation is a process where the growth mediu m is provided in the fermenter from the start, where the fermenter is inoculated with an intended microbial cel l and the fermentation process is ru nning until a predetermined condition has been reached, typical ly depletion of the growth medium and the cessation of microbial growth caused by the depletion. A fed-batch fermentation is a process where a part of the growth medium is provided from the start of the fermentation process where the inocu lu m is added, and at a certain time point after the start of the fermentation additional su bstrate, the feed medium, is fed to the fermenter at a rate that may be predetermined or determined by the conditions in the fermenter, u ntil the maximal volu me has been reached. The feed medium may or may not have the same com position as the initial growth mediu m.

A continuous fermentation is a process where new growth mediu m is continuously fed to the fermenter and fermentation broth is simu ltaneously removed from the fermenter at the same rate so the volume in the fermenter is constant. I n industrial fermentation processes are typical ly conducted by first providing a growth medium in a fermenter, inocu lating the fermenter with an inocu lu m com prising a microbial cel l and fermenting u nder defined conditions such as pH, temperatu re, oxygen level etc., at a predefined time or until a predefined condition, e.g. titer, oxygen consu mption, has been reached.

I n a preferred embodiment, a fed-batch fermentation process is performed prior to steps a) and b) of the method of the present invention.

The inocu lu m is in general a liquid culture of the microorganism used for the fermentation prepared in a seed fermenter, a seed fermenter typical ly having a volume of 5-15 % of the main fermenter used for production. The growth mediu m for the seed fermenter may or may not be the same growth mediu m as used in the main fermenter.

Thus the inocu lum is typical ly prepared from a vial containing the production strain of the host cel l (preferably a microorganism) , where the content of the vial first is inoculated in a smal l volu me and the host cel ls are grown to a desired density to prepare a first cu lture of the production strain, where after the first cu lture the production strain is inocu lated in the next of a series of seed fermenters of increasing size, where the volu me increases 5-20 fold in each step u ntil a sufficient volu me to inoculate the production fermenter has been reached. Such a series of fermenters in increasing size is also known as a seed train (W02017/068012 Al) .

Thus, du ring the fermentation process, a microorganism com prising a nucleic acid sequence encoding the protein of interest is inoculated and cultivated in a fermentation medium. Preferably, the microorganism is a recom binant microorganism.

Any medium suitable for the cu ltu re of the particular microbial cel l may be used. The fermentation medium may be a minimal medium as described before, e.g., in WO 98/37179, or the fermentation mediu m may be a com plex medium com prising com plex nitrogen and/or carbon sou rces, wherein the com plex nitrogen sou rce may be partial ly hyd rolyzed as described in WO 2004/003216. Fu rthermore, the fermentation mediu m may contain a phosphate and/or carbonate sou rce. The phosphate can be added to the fermentation medium in chemical ly defined form by adding one or more phosphate salts such as potassium phosphate, sodiu m phosphate, magnesium phosphate and combinations thereof. The concentration of phosphate in the fermentation mediu m at the beginning of the cu ltu re process may be between 2 and 19 g/L of the initial fermentation mediu m.

The present invention may be usefu l for recovering a protein from any fermentation process in industrial scale, i.e., at least 1,000 liters, more preferably at least 5,000 liters, even more preferably at least 50,000 liters.

Downstream processing

After the method of the present invention has been performed, the resu lting protein may be fu rther pu rified by methods known in the art. For exam ple, the protein may be recovered by conventional procedures including, but not limited to, filtration, e.g., ultra-filtration and micro-filtration, centrifugation, e.g. with a nozzle separator, extraction, spray-d rying, evaporation, precipitation or crystal lization.

The isolated polypeptide may then be fu rther pu rified by a variety of procedu res known in the art including, but not limited to, ch romatography (e.g., ion exchange, affinity,

hyd rophobic, ch romatofocusing, and size exclusion) , electrophoretic procedu res (e.g., preparative isoelectric focusing (I EF), differential solubility (e.g., am monium su lfate precipitation) , or extraction (see, e.g., Protein Pu rification, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989) . The purified polypeptide may then be

concentrated by procedu res known in the art including, but not limited to, u ltrafiltration and evaporation, in particu lar, thin fil m evaporation.

Protein formu lation

I n another embodiment of the invention, the inventive methods fu rther com prise a step d) of preparing a formu lation containing the protein of interest.

“Protein formu lation” means any non-com plex formu lation com prising a smal l nu m ber of ingredients, wherein the ingredients serve the pu rpose of stabilizing the proteins comprised in the protein formulation and/or the stabilization of the protein formu lation itself. The term “protein stability” relates to the retention of proteins activity as a fu nction of time du ring storage or operation. The term“protein formulation stability” relates to the maintenance of physical appearance of the protein formulation du ring storage or operation as wel l as the avoidance of microbial contamination du ring storage or operation.

The protein formu lation can be either solid or liquid. Protein formulations can be obtained by using techniques known in the art. For instance, without being limited thereto, solid enzyme formulations can be obtained by extrusion or granu lation. Suitable extrusion and granu lation tech niques are known in the art and are described for instance in WO 94/19444 A1 and WO 97/43482 Al.

Host cel l According to the invention, the protein of interest may be obtained from any host cel l. The host cel l may be a eukaryotic or a prokaryotic cel l.

I n a preferred em bodiment, the host cel l may be a microorganism or microbial cel l. I n one embodiment, the microorganism is a bacteria, an archaea, a fungal cel l or a yeast cel l.

I n an em bodiment of the invention, the host cel l may be a bacterium.

Bacterial cel ls include gram positive or gram negative bacteria. Preferably, the bacterial cel ls are gram-positive. Gram-positive bacteria include, but are not limited to, Bacillus, Brevibacterium, Corynebacterium, Streptococcus, Streptomyces, Staphylococcus,

Enterococcus, Lactobacillus, Lactococcus, Clostridium, Geobacillus, and OceanobaciHus.

I n the methods of the present invention, the bacterial cel l may be any Bacillus cel l. Bacillus cel ls usefu l in the practice of the present invention include, but are not limited to, Bacillus alkalophilus, Bacillus amyloliquefaciens, Bacillus brevis, Bacillus circulans, Bacillus dausii, Bacillus coagu/ans, Bacillus firmus, Bacillus lautus, Bacillus lentus, Bacillus Hcheniformis, Bacillus megaterium, Bacillus pumi/us, Bacillus stearothermophilus, Bacillus

methylotrophicus, Bacillus cereus Bacillus paralicheniformis, Bacillus subti/is, and Bacillus thuringiensis cel ls. I n one em bodiment, the bacterial host cel l is a Bacillus

amyloliquefaciens, Bacillus lentus, Bacillus Hcheniformis, Bacillus stearothermophilus or Bacillus subti/is cel l. I n another embodiment, the bacterial host cel l is a Bacillus

Hcheniformis cel l or a Bacillus subti/is cel l. I n one embodiment, the Bacil lus cel l is a Bacillus cel l of Bacillus subti/is, Bacillus pumi/us, Bacillus Hcheniformis, or Bacillus lentus.

Preferably, the cel l is a Bacillus Hcheniformis cel l.

I n the methods of the present invention, the bacterial cel l may be Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus gasseri, Lactobacillus bulgaricusk, Lactobacillus reuteri, Escherichia coH, Staphylococcus aureus, Corynebacteriu m glutamicu m,

Corynebacterium acetoglutamicum, Corynebacterium acetoacidophilum, Corynebacterium ca unae, Corynebacterium ammoniagenes, Corynebacterium thermoaminogenes,

Corynebacterium melassecola, Corynebacterium effiziens, Corynebacterium efficiens, Corynebacterium desert, Brevibacterium flavum, Brevibacterium lactofermentum,

Brevibacterium divarecatum, Pseudomonas putida, Pseudomonas syringae, Streptomyces coelicolor, Streptomyces Hvidans, Streptomyces a /bus, Streptomyces avermiti/is,

duconobacter oxydans, duconobacter morbifer, duconobacter thailandicus, Acetobacter aceti, Clostridium acetobutylicum, Clostridium saccharobutylicum, Clostridium beijerinckii, Streptococcus equisimi/is, Streptococcus pyogenes, Streptococcus uberis, Streptococcus equi subsp., Zooepidemicus or Basfia succiniciproducens.

Some other preferred bacteria include strains of the order Actinomycetales, preferably, Streptomyces, preferably Streptomyces spheroides { ATTC 23965) , Streptomyces

thermovio/aceus (I FO 12382) , Streptomyces Hvidans or Streptomyces murinus or

StreptoverticiHum vertici/Hum ssp. verticHHum. Other preferred bacteria include Rhodobacter sphaeroides, Rhodomonas palustri, Streptococcus tactis. Further preferred bacteria include strains belonging to Myxococcus, e.g., M. virescens.

Gram-negative bacteria include, but are not limited to, Escherichia, Pseudomonas,

Salmonella, Campylobacter, Helicobacter, Acetobacter, F/avobacterium, Fusobacterium, Gluconobacter. I n a specific embodiment, the bacterial host cel l is a Echerichia coH cel l. Another gram negative bacteria is Pseudomonas purrocinia (ATCC 15958) or Pseudomonas f/uorescens (N RRL B-l l) , or Basfia succiniciproducens. Fu rther the gram-negative Bacteria include Butiauxella, more specifical ly Butiauxella agrestis, Butiauxella brennerae,

Butiauxella ferragutiae, Butiauxella gaviniae, Butiauxella izardii, Butiauxella noackiae, and Butiauxella warmbo/diae.

I n a specific embodiment, the microorganism may be of the genus Bacillus, Streptomyces, Escherichia, Buttiauxella and Pseudomonas.

The microbial cel l may be a fungal cel l. "Fu ngi" as used herein includes the phyla

Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota as wel l as the Oomycota and Deuteromycotina and al l mitosporic fu ngi. Representative groups of Ascomycota incl ude, e.g., Neurospora, EupeniciHium (=Penici//ium), Emericella (= Aspergillus) , Eurotium (= Aspergillus), Myceliophthora, Cl, and the true yeasts listed below. Exam ples of

Basidiomycota include mush rooms, rusts, and smuts. Representative grou ps of

Chytridiomycota include, e.g., AHomyces, Blastocladiella, Coelomomyces, and aquatic fungi. Representative groups of Oomycota include, e.g. Saprolegniomycetous aquatic fungi (water molds) such as Achlya. Exam ples of mitosporic fungi include Aspergillus, e.g., Aspergillus niger, PeniciHium, Candida, and A/ternaria. Representative grou ps of Zygomycota include, e.g., Rhizopus and Mu cor.

Some preferred fu ngi include strains belonging to the su bdivision Deuteromycotina, class Hyphomycetes, e.g., Fusarium, Hu mi col a, Tricoderma, Myrothecium, VerticiHum,

Arthromyces, Ca/dariomyces, Ulocladium, Embellisia, Cladosporium or Dreschlera, in particu lar Fusarium oxysporum (DSM 2672), Humic oia in so tens, Trichoderma resii,

Myrothecium verrucana (I FO 6113) , VerticiHum aiboatrum, VerticiHum dahiie, Arthromyces ramosus (FERM P-7754) , Ca/dariomyces fumago, Ulocladium chartarum, Embellisia alii or Dreschlera haiodes.

Other preferred fu ngi include strains belonging to the su bdivision Basidiomycotina, class Basidiomycetes, e.g. Coprinus, Phanerochaete, Corioius or Trametes, in particu lar Coprinus cinereus f. microsporus (I FO 8371) , Coprinus macrorhizus, Phanerochaete chrysosporium (e.g. NA-12) or Trametes (previously cal led Poiyporus) , e.g. T versicolor {eg. PR4 28-A).

Fu rther preferred fu ngi include strains belonging to the su bdivision Zygomycotina, class Mycoraceae, e.g. Rhizopus or Mucor, in particu lar Mucor hiemaiis.

The microbial cel l may be a yeast cel l. "Yeast" as used herein includes ascosporogenous yeast (Endomyceta/es) , basidiosporogenous yeast, and yeast belonging to the Fungi I m perfecti ( B/astomycetes ) . The ascosporogenous yeasts are divided into the families Spermophthoraceae and Saccharomycetaceae. The latter is comprised of fou r su bfamilies, Schizosaccharomycoideae (e.g., genus Schizosaccharomyces) , Nadsonioideae,

Lipomycoideae, and Saccharomycoideae (e. g. genera Kluyveromyces, Pichia, and

Saccharomyces) . The basidiosporogenous yeasts include the genera Leucosporidim, Rhodosporidium, Sporidiobo/us, FHobasidium, and Filobasidiella. Yeasts belonging to the Fu ngi I m perfecti are divided into two families, Sporobolomycetaceae (e.g., genera

Sporobolomyces and Bullera ) and Cryptococcaceae (e.g. genus Candida) . I n another embodiment, the fungal host cel l is a filamentous fungal cel l, e.g., Ashbya spec, preferably Ashbya gossypii ( Eremothecium gossypit) .

Preferably, the fungal strain is selected from the grou p consisting of Aspergillus niger, Trichoderma reesei and Pichia pas tor is.

I n an embodiment, the host cell may also be a eu karyote, such as a mammalian cel l, an insect cel l, or a plant cel l.

I n one embodiment, the cel l com prises one or more genetic constructs for heterologous gene expression.

Protein of interest

The present invention involves a process for recovering a microorganism in order to produce a protein of interest.

I n a preferred em bodiment, the protein of interest is an enzyme.

The enzyme may have one or more binding sites for a divalent cation. The enzyme thus may have a binding site for Ca ²⁺ , Mg ²⁺ , Ba ²⁺ , Pb ²⁺ , Fe ²⁺ , Zn ²⁺ , Ni ²⁺ , Cu ²⁺ , M n ²⁺ , Sr ²⁺ , Co ²⁺ , Be ²⁺ or Ra ²⁺ . Preferably, the enzyme has a binding site for Ca ²⁺ and/or Mg ²⁺ . Enzymes having a binding site for Ca ²⁺ and/or Mg ²⁺ are known to the skil led person. Preferably, the enzyme is a protease or an amylase. The protease is preferably an al kaline protease, preferably a serine-protease, more preferably a su btilisin protease. The amylase is preferably an al pha- amylase.

Fu rther, the enzyme may have an isoelectric point (pi) below pH 11. Preferably, the pi pf the enzyme is one pH u nit, more preferably two pH units below pH 11. The isoelectric point of an enzyme is the pH at which the enzyme carries no net electrical charge or is electrical ly neutral in the statistical mean. The pi may be determined by methods known in the art, e.g. by gel electrophoresis using a buffer which determines the pH of the electrophoretic gel. If the pH of the buffer is above the pi of the protein being analyzed, the protein wil l migrate to the positive pole. If the pH of the buffer is below the pi of the protein being analyzed, the protein wil l migrate to the negative pole of the gel. If the buffer pH is equal to the pi of the protein being analyzed, the protein wil l not migrate within the gel at al l. I n another embodiment, the enzyme is stable at a pH above pH 11. An enzyme is stable at a certain pH, if the enzyme retains its native folded conformation, i.e. is not in a denatu red (unfolded or extended) state.

I n a preferred em bodiment, the enzyme is selected from the group consisting of amylase, al pha-amylase, glucoamylase, pul lu lanase, protease, metal loprotease, peptidase, lipase, cutinase, acyl transferase, cel lu lase, endoglucanase, glucosidase, cel lu biohyd rolase, xylanase, xyloglucantransferase, xylosidase, mannanase, phytase, phosphatase, xylose isomerase, glucoase isomerase, lactase, acetolactate decarboxylase, pectinase, pectin methylesterase, polygalactu ronidase, lyase, pectate lyase, arabinase, arabinofuranosidase, galactanase, a laccase, peroxidase and an asparaginase, preferably wherein the enzyme is an amylase or protease.

I n a particu lar preferred embodiment, the fol lowing enzymes are preferred:

Protease

Enzymes having proteolytic activity are cal led“proteases” or“peptidases”. Proteases are active proteins exerting“protease activity” or“proteolytic activity”.

Proteases are mem bers of class EC 3.4. Proteases include aminopeptidases (EC 3.4.11) , dipeptidases (EC 3.4.13), dipeptidyl-peptidases and tripeptidyl-peptidases (EC 3.4.14) , peptidyl-dipeptidases (EC 3.4.15) , serine-type carboxypeptidases (EC 3.4.16),

metal locarboxypeptidases (EC 3.4.17), cysteine-type carboxypeptidases (EC 3.4.18) , omega peptidases (EC 3.4.19) , serine endopeptidases (EC 3.4.21) , cysteine endopeptidases (EC 3.4.22), aspartic endopeptidases (EC 3.4.23), metal lo-endopeptidases (EC 3.4.24) , th reonine endopeptidases (EC 3.4.25), endopeptidases of u nknown catalytic mechanism (EC 3.4.99) .

Com mercial ly available protease enzymes include, but are not limited, to Lavergy™ Pro (BASF) ; Alcalase ^® , Blaze ^® , Du ralase™, Du razym™, Relase ^® , Relase ^® U ltra, Savinase ^® , Savinase ^® U ltra, Primase ^® , Polarzyme ^® , Kannase ^® , Liquanase ^® , Liquanase ^® U ltra,

Ovozyme ^® , Coronase ^® , Coronase ^® U ltra, Neutrase ^® , Everlase ^® and Esperase ^® (Novozymes A/S) , those sold under the tradename Maxatase ^® , Maxacal ^® , Maxapem ^® , Purafect ^® , Pu rafect ^® Prime, Pu rafect MA ^® , Pu rafect Ox ^® , Purafect OxP ^® , Puramax ^® , Properase ^® ,

FN2 ^® , FN3 ^® , FN4 ^® , Excel lase ^® , Eraser ^® , U ltimase ^® , Opticlean ^® , Effectenz ^® , Preferenz ^® and Optimase ^® (Danisco/DuPont) , Axapem™ (Gist-Brocases N.V.) , Bacillus /entus Al kaline Protease, and KAP {Bacillus alkalophilus su btilisin) from Kao.

I n one embodiment the protease may be selected from serine proteases (EC 3.4.21) . Serine proteases or serine peptidases (EC 3.4.21) are characterized by having a serine in the cata lytica I ly active site, which forms a covalent adduct with the su bstrate du ring the catalytic reaction. A serine protease may be selected from the group consisting of chymotrypsin (e.g., EC 3.4.21.1) , elastase (e.g., EC 3.4.21.36, EC 3.4.21.37 or EC 3.4.21.71), granzyme (e.g., EC 3.4.21.78 or EC 3.4.21.79), kal likrein (e.g., EC 3.4.21.34, EC 3.4.21.35, EC 3.4.21.118, or EC 3.4.21.119,) plasmin (e.g., EC 3.4.21.7) , trypsin (e.g., EC 3.4.21.4), th rom bin (e.g., EC 3.4.21.5,) and subtilisin (also known as subtilopeptidase, e.g., EC 3.4.21.62), the latter hereinafter also being referred to as“subtilisin”.

A sub-group of the serine proteases tentatively designated subtilases has been proposed by Siezen et al. (1991), Protein Eng. 4:719-737 and Siezen et al. (1997), Protein Science 6:501- 523. They are defined by homology analysis of more than 170 amino acid sequences of serine proteases previously referred to as subtilisin-like proteases. A subtilisin was previously often defined as a serine protease produced by Gram-positive bacteria or fungi, and according to Siezen et al. now is a subgroup of the subtilases. A wide variety of subtilases have been identified, and the amino acid sequence of a number of subtilases has been determined. For a more detailed description of such subtilases and their amino acid sequences reference is made to Siezen et al. (1997), Protein Science 6:501-523.

The subtilases may be divided into 6 sub-divisions, i.e. the subtilisin family, thermitase family, the proteinase K family, the lantibiotic peptidase family, the kexin family and the pyrolysin family.

A subgroup of the subtilases are the subtilisins, which are serine proteases from the family S8 as defined by the MEROPS database (accessible under merops.sanger.ac.uk). Peptidase family S8 contains the serine endopeptidase subtilisin and its homologues. In subfamily S8A, the active site residues frequently occur in the motifs Asp-Thr/Ser-Gly, His-Gly-Thr- His and Gly-Thr-Ser-Met-Ala-Xaa-Pro. Most members of the peptidase family S8 are active at neutral-mildly alkali pH. Many peptidases in the family are thermostable.

Prominent members of family S8, subfamily A are:

Proteases of the subtilisin type (EC 3.4.21.62) and variants may be bacterial proteases. Said bacterial protease may be from a Gram-positive bacterium such as Bacillus, Clostridium, Enterococcus, Geobacillus, Lactobacillus, Lactococcus, OceanobaciHus, Staphylococcus, Streptococcus, or Streptomyces, or a Gram-negative bacterium such as a Campylobacter, E. coH, F/avobacterium, Fusobacterium, Helicobacter, Hyobacter, Neisseria, Pseudomonas, Salmonella, or Ureap/asma. A review of this family is provided, for example, in "Subtilases: Subtilisin-like Proteases" by R. Siezen, pages 75-95 in "Subtilisin enzymes", edited by R. Bott and C. Betzel, New York, 1996. At least one protease may be selected from the following: subtilisin from Bacillus

amyloliquefaciens BPU' (described by Vasantha et al. (1984) J. Bacteriol. Volume 159, p. 811-819 and JA Wells et al. (1983) in Nucleic Acids Research, Volume 11, p. 7911-7925); subtilisin from Bacillus Hcheniformis (subtilisin Carlsberg; disclosed in EL Smith et al.

(1968) in J. Biol Chem, Volume 243, pp. 2184-2191, and Jacobs et al. (1985) in Nucl. Acids Res, Vol 13, p. 8913-8926); subtilisin PB92 (original sequence of the alkaline protease PB92 is described in EP 283075 A2); subtilisin 147 and/or 309 (Esperase ^® , Savinase ^® ,

respectively) as disclosed in WO 89/06279; subtilisin from Bacillus lentus as disclosed in WO 91/02792, such as from Bacillus lentus DSM 5483 or the variants of Bacillus lentus DSM 5483 as described in WO 95/23221; subtilisin from Bacillus alcalophilus { DSM 11233) disclosed in DE 10064983; subtilisin from Bacillus gibsonii (DSM 14391) as disclosed in WO 2003/054184; subtilisin from Bacillus sp. (DSM 14390) disclosed in WO 2003/056017;

subtilisin from Bacillus sp. (DSM 14392) disclosed in WO 2003/055974; subtilisin from Bacillus gibsonii (DSM 14393) disclosed in WO 2003/054184; subtilisin having SEQ ID NO: 4 as described in WO 2005/063974; subtilisin having SEQ I D NO: 4 as described in WO 2005/103244; subtilisin having SEQ ID NO: 7 as described in WO 2005/103244; and subtilisin having SEQ ID NO: 2 as described in application DE 102005028295.4.

Proteases also include the variants described in: WO 92/19729, WO 95/23221, WO

96/34946, WO 98/20115, WO 98/20116, WO 99/11768, WO 01/44452, WO 02/088340, WO 03/006602, WO 2004/03186, WO 2004/041979, WO 2007/006305, WO 2011/036263,

WO 2011/036264, and WO 2011/072099. Suitable examples comprise especially protease variants of subtilisin protease derived from SEQ ID NO:22 as described in EP 1 921 147 with amino acid substitutions in one or more of the following positions: 3, 4, 9, 15, 24, 27, 33, 36, 57, 68, 76, 77, 87, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 106, 118, 120, 123, 128, 129,

130, 131, 154, 160, 167, 170, 194, 195, 199, 205, 206, 217, 218, 222, 224, 232, 235, 236, 245, 248, 252 and 274 which have proteolytic activity. I n addition, a subtilisin protease is not mutated at positions Asp32, His64 and Ser221.

A subtilisin-like enzyme may have SEQ ID NO:22 as described in EP 1921147, or may be a variant thereof which is at least 80%, at least 90%, at least 95% or at least 98% identical to SEQ ID NO:22 as described in EP 1 921 147 and has proteolytic activity. In one embodiment, a subtilisin-like enzyme is at least 80%, at least 90%, at least 95% or at least 98% identical to SEQ ID NO:22 as described in EP 1 921 147 and is characterized by having amino acid glutamic acid (E), or aspartic acid (D), or asparagine (N), or glutamine (Q), or alanine (A), or glycine (G), or serine (S) at position 101 (according to BPN’ numbering) and has proteolytic activity. In one embodiment, a subtilisin-like enzyme is at least 80%, at least 90%, at least 95% or at least 98% identical to SEQ ID NO:22 as described in EP 1 921 147 and is characterized by having amino acid glutamic acid (E), or aspartic acid (D), at position 101 (according to BPN’ numbering) and has proteolytic activity. Such a subtilisin variant may comprise an amino acid substitution at position 101, such as R101E or R101D, alone or in combination with one or more substitutions at positions 3, 4, 9, 15, 24, 27, 33, 36, 57, 68, 76, 77, 87, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 106, 118, 120, 123, 128, 129, 130, 131, 154, 160, 167, 170, 194, 195, 199, 205, 206, 217, 218, 222, 224, 232, 235, 236, 245, 248, 252 and/or 274 (according to BPN’ numbering) and has proteolytic activity. I n one embodiment, said protease com prises one or more fu rther su bstitutions (a) to (h) : (a) th reonine at position 3 (3T) , (b) isoleucine at position 4 (41) , (c) alanine, threonine or arginine at position 63 (63A, 63T, or 63R), (d) aspartic acid or glutamic acid at position 156 (156D or 156E), (e) proline at position 194 (194P) , (f) methionine at position 199 (199M) , (g) isoleucine at position 205 (2051) , (h) aspartic acid, glutamic acid or glycine at position 217 (217D, 217E or 217G) , (i) com binations of two or more amino acids according to (a) to (h).

A su btilisin-like enzyme may have an amino acid sequence being at least 80% identical to SEQ I D NO:22 as described in EP 1 921 147 and being fu rther characterized by com prising the su bstitution R101E, and one or more su bstitutions selected from the group consisting of S156D, L262E, Q137H , S3T, R45E,D,Q, P55N, T58W,Y,L, Q59D,M ,N ,T, G61 D,R, S87E, G97S, A98D,E,R, S106A,W, N 117E, H 120V,D,K,N, S125M, P129D, E136Q, S144W, S161T, S163A,G, Y171 L, A172S, N 185Q, V199M, Y209W, M222Q, N238H, V244T, N261T,D and L262N ,Q,D (as described in WO 2016/096711 and according to the BPN’ nu mbering) , and has proteolytic activity.

Proteases used in the present invention have proteolytic activity. The methods for determining proteolytic activity are wel l-known in the literature (see e.g. Gu pta et al. (2002), Appl. Microbiol. Biotech nol. 60: 381-395). Proteolytic activity may be determined by using Succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (Suc-AAPF-pNA, short AAPF; see e.g. Del Mar et al. (1979) , Analytical Biochem 99, 316-320) as substrate. pNA is cleaved from the su bstrate molecule by proteolytic cleavage, resulting in release of yel low color of free pNA which can be quantified by measuring OD405.

Amylase

Al pha-amylase (E.C. 3.2.1.1) enzymes may perform endohydrolysis of (l->4) -al pha-D- glucosidic linkages in polysaccharides containing th ree or more (l->4) -al pha-lin ked D- glucose u nits. Amylase enzymes act on starch, glycogen and related polysaccharides and oligosaccharides in a random man ner; reducing grou ps are liberated in the al pha- configu ration. Other examples of amylase enzymes include: Beta-amylase (E.C. 3.2.1.2) , Glucan 1,4-al pha-maltotetraohydrolase (E.C. 3.2.1.60) , Isoamylase (E.C. 3.2.1.68), Glucan 1,4-al pha-maltohexaosidase (E.C. 3.2.1.98) , and Glucan 1,4-al pha-maltohyd rolase (E.C. 3.2.1.133) .

Amylase enzymes have been described in patent documents including, but not limited to: WO 2002/068589, WO 2002/068597, WO 2003/083054, WO 2004/091544, and WO

2008/080093.

An amylase derived from Bacillus Hcheniformis has SEQ I D NO:2 as described in WO

95/10603. Suitable variants of this amylase are those which are at least 90% identical to SEQ I D NO: 2 as described in WO 95/10603 and/or com prise one or more substitutions in the fol lowing positions: 15, 23, 105, 106, 124, 128, 133, 154, 156, 178, 179, 181, 188, 190,

197, 201, 202, 207, 208, 209, 211, 243, 264, 304, 305, 391, 408, and 444 and have amylolytic activity. Such variants are described in WO 94/02597, WO 94/018314, WO 97/043424 and SEQ ID NO:4 of WO 99/019467.

An amylase derived from B. stearothermophf/us has SEQ ID NO:6 as described in

WO 02/10355. Suitable variants of this amylase are those which are at least 90% identical thereto and have amylolytic activity. Suitable variants of SEQ ID NO:6 include those which are at least 90% identical to SEQ I D NO:6 as described in WO 02/10355 and/or further comprise a deletion in positions 181 and/or 182 and/or a substitution in position 193.

An amylase derived from Bacillus sp.707 has SEQ ID NO:6 as disclosed in WO 99/19467 or is at least 90% identical thereto having amylolytic activity.

An amylase derived from Bacillus halmapalus has SEQ ID NO:2 or SEQ ID NO:7 as described in WO 96/23872, also described as SP-722, or is at least 90% identical to one of the sequences which has amylolytic activity.

An amylase derived from Bacillus sp. DSM 12649 has SEQ ID NO:4 as disclosed in

WO 00/22103 or is at least 90% identical thereto having amylolytic activity.

An amylase derived from Bacillus strain TS-23 has SEQ ID NO:2 as disclosed in

WO 2009/061380 or is at least 90 % identical thereto having amylolytic activity.

An amylase derived from Cytophaga sp. has SEQ ID NO:l as disclosed in WO 2013/184577 or is at least 90% identical thereto having amylolytic activity.

An amylase derived from Bacillus megaterium DSM 90 has SEQ ID NO:l as disclosed in WO 2010/104675 or is at least 90% identical thereto having amylolytic activity.

Amylases are known having amino acids 1 to 485 of SEQ ID NO:2 as described in

WO 00/60060 or amylases comprising an amino acid sequence which is at least 96% identical to amino acids 1 to 485 of SEQ ID NO:2 which have amylolytic activity.

Amylases are also known having SEQ ID NO: 12 as described in WO 2006/002643 or amylases having at least 80% identity thereto and have amylolytic activity. Suitable amylases include those having at least 80% identity compared to SEQ ID NO:12 and/or comprising the substitutions at positions Y295F and M202LITV and have amylolytic activity.

Amylases are also known having SEQ I D NO:6 as described in WO 2011/098531 or amylases having at least 80% identity thereto having amylolytic activity. Suitable amylases include those having at least 80% identity compared to SEQ ID NO:6 and/or comprising a substitution at one or more positions selected from the group consisting of 193 [G,A,S,T or M], 195 [F,W,Y,L,I or V], 197 [F,W,Y,L,I or V], 198 [Q or N], 200 [F,W,Y,L,I or V], 203

[F,W,Y,L,I or V], 206 [F,W,Y,N,L,I,V,H,Q,D or E], 210 [F,W,Y,L,I or V], 212 [F,W,Y,L,I or V],

213 [G,A,S,T or M] and 243 [F,W,Y,L,I or V] and have amylolytic activity. Amylases are known having SEQ I D NO:l as described in WO 2013/001078 or amylases having at least 85% identity thereto having amylolytic activity. Suitable amylases include those having at least 85% identity compared to SEQ I D NO:l and/or comprising an alteration at two or more (several) positions corresponding to positions G304, W140, W189, D134, E260, F262, W284, W347, W439, W469, G476, and G477 and having amylolytic activity.

Amylases are known having SEQ ID NO:2 as described in WO 2013/001087 or amylases having at least 85% identity thereto and having amylolytic activity. Suitable amylases include those having at least 85% identity compared to SEQ I D NO:2 and/or comprising a deletion of positions 181 + 182, or 182 + 183, or 183+184, which have amylolytic activity. Suitable amylases include those having at least 85% identity compared to SEQ ID NO:2 and/or comprising a deletion of positions 181 + 182, or 182+183, or 183 + 184, which comprise one or two or more modifications in any of positions corresponding to W140, W159, W167, Q169, W189, E194, N260, F262, W284, F289, G304, G305, R320, W347, W439, W469, G476 and G477 and have amylolytic activity.

Amylases also include hybrid a -amylases of the above mentioned amylases as for example as described in WO 2006/066594.

Commercially available amylase enzymes include: Amplify ^® , Duramyl™, Termamyl™, Fungamyl™, Stainzyme™, Stainzyme Plus™, Natalase™, Liquozyme X and BAN™ (from Novozymes A/S), and Rapidase™, Purastar™, PoweraseTM, Effectenz™ (M100 from

DuPont), Preferenz™ (S1000, S110 and F1000; from DuPont), PrimaGreen™ (ALL; DuPont), Optisize™ (DuPont).

In one embodiment, the enzyme is a Termamyl-like amylase. In the present context, the term“Termamyl-like enzyme” is intended to indicate an a -amylase, which, at the amino acid level, has a sequence identity of at least 60% to the B. Hcheniformis a -amylase described in WO 96/23874. In an embodiment, the Termamyl-like a -amylase displays at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 99% identity to the B. Hcheniformis a -amylase described in WO 96/23874.

Another a -amylase herein is Natalase or a variant thereof as described in WO 95/26397, WO 99/19467 and WO 01/66712.

Lipase

“Lipase”,“lipolytic enzyme”,“lipid esterase”, all refer to an enzyme of EC class 3.1.1

(“carboxylic ester hydrolase”). Lipases (E.C. 3.1.1.3, Triacylglycerol lipase) may hydrolyze triglycerides to more hydrophilic mono- and diglycerides, free fatty acids, and glycerol. Lipase enzymes usually includes also enzymes which are active on substrates different from triglycerides or cleave specific fatty acids, such as Phospholipase A (E.C. 3.1.1.4), Galactolipase (E.C. 3.1.1.26), cutinase (EC 3.1.1.74), and enzymes having sterol esterase activity (EC 3.1.1.13) and/or wax-ester hydrolase activity (EC 3.1.1.50). Many lipase enzymes have been described in the prior art, including, but not being limited to: WO 00/032758, WO 03/089620, WO 2005/032496, WO 2005/086900, WO 2006/00976, WO 2006/031699, WO 2008/036863, WO 2011/046812, and WO 2014/059360.

Cellulase

"Cellulases",“cellulase enzymes” or“cellulolytic enzymes” are enzymes involved in the hydrolysis of cellulose. Three major types of cellulases are known, namely endo-beta-1,4- glucanase (endo-l,4-P-D-glucan 4-glucanohydrolase, E.C. 3.2.1.4; hydrolyzing - 1,4- glucosidic bonds in cellulose), cellobiohydrolase (1,4-P-D-glucan cellobiohydrolase, EC 3.2.1.91), and beta-glucosidase (EC 3.2.1.21).

Cellulase enzymes have been described in patents and published patent applications including, but not limited to: WO 97/025417, WO 98/024799, WO 03/068910, WO

2005/003319, and WO 2009/020459.

Commercially available cellulase enzymes include Celluzyme™, Endolase™, Carezyme™,

Cel I u soft™, Renozyme™, Celluclean™ (from Novozymes A/S), Ecostone™, Biotouch™, Econase™, Ecopulp™ (from AB Enzymes Finland), Clazinase™, and Puradax HA™,

Genencor detergent cellulase L, IndiAge™ Neutra (from Genencor International

Inc. /DuPont), Revitalenz™ (2000 from DuPont), Primafast™ (DuPont) and KAC-500™ (from Kao Corporation).

Cellulases used in the methods according to the invention have“cellulolytic activity” or “cellulase activity”. Assays for measurement of cellulolytic activity are known to those skilled in the art. For example, cellulolytic activity may be determined by virtue of the fact that cellulase hydrolyses carboxymethyl cellulose to reducing carbohydrates, the reducing ability of which is determined colorimetrically by means of the ferricyanide reaction, according to Hoffman, W. S., J. Biol. Chem. 120, 51 (1937).

Mannanase

Mannase (E.C. 3.2.1.78) enzymes hydrolyse internal S -1,4 bonds in mannose polymers. “Mannanase” may be an alkaline mannanase of Family 5 or 26. Mannanase enzymes are known to be derived from wild-type from Bacillus or Humicola, particularly B.

agaradhaerens, B. Hcheniformis, B. halodurans, B. dausii, or H. inso/ens. Suitable mannanases are described in WO 99/064619.

Commercially available mannanase enzymes include, but are not limited to, Mannaway ^® (Novozymes AIS).

Pectate lyase

Pectate lyase (E.C. 4.2.2.2) enzymes catalyze eliminative cleavage of (l->4)-alpha-D- galacturonan to give oligosaccharides with 4-deoxy-alpha-D-galact-4-enuronosyl groups at their non-reducing ends. Pectate lyase enzymes have been described in patents and published patent applications including, but not limited to: WO 2004/090099. Pectate lyases are known to be derived from Bacillus, particularly B. Hcheniformis or B. agaradhaerens, or a variant derived of any of these, e.g. as described in US 6,124,127, WO 99/027083, WO 99/027084, WO 2002/006442, WO 02/092741, WO 03/095638.

Commercially available pectate lyase enzymes include: XpectTM, PectawashTM and PectawayTM (Novozymes A/S); PrimaGreenTM, EcoScour (DuPont).

Nuclease

Nuclease (EC 3.1.21.1), also known as Deoxyribonuclease I, or Dnase, performs

endonucleolytic cleavage to 5'-phosphodinucleotide and 5'-phosphooligonucleotide end- products.

Nuclease enzymes have been described in patents and published patent applications including, but not limited to: US 3,451,935, GB 1300596, DE 10304331, WO 2015/155350, WO 2015/155351, WO 2015/166075, WO 2015/181287, and WO 2015/181286.

Enzyme variants may be defined by their sequence identity when compared to a parent enzyme. Sequence identity usually is provided as“% sequence identity” or“% identity”. To determine the percent-identity between two amino acid sequences in a first step a pairwise sequence alignment is generated between those two sequences, wherein the two sequences are aligned over their complete length (i.e., a pairwise global alignment). The alignment is generated with a program implementing the Needleman and Wunsch algorithm (J. Mol. Biol. (1979) 48, p. 443-453), preferably by using the program“NEEDLE” (The European Molecular Biology Open Software Suite (EMBOSS)) with the programs default parameters (gapopen = 10.0, gapextend=0.5 and matrix=EBLOSUM62). The preferred alignment for the purpose of this invention is that alignment, from which the highest sequence identity can be determined.

After aligning the two sequences, in a second step, an identity value shall be determined from the alignment. Therefore, according to the present invention the following calculation of percent-identity applies:

%-identity = (identical residues / length of the alignment region which is showing the respective sequence of this invention over its complete length) *100. Thus sequence identity in relation to comparison of two amino acid sequences according to this

embodiment is calculated by dividing the number of identical residues by the length of the alignment region which is showing the respective sequence of this invention over its complete length. This value is multiplied with 100 to give“%-identity”.

For calculating the percent identity of two DNA sequences the same applies as for the calculation of percent identity of two amino acid sequences with some specifications. For DNA sequences encoding for a protein the pairwise alignment shal l be made over the com plete length of the coding region from start to stop codon excluding introns. For non- protein-coding DNA sequences the pairwise align ment shal l be made over the complete length of the sequence of this invention, so the complete sequence of this invention is com pared to another sequence, or regions out of another sequence. Moreover, the preferred alignment program im plementing the Need leman and Wunsch algorith m (J. Mol. Biol. (1979) 48, p. 443-453) is“N EEDLE” (The Eu ropean Molecular Biology Open Software Suite

(EM BOSS)) with the programs default parameters (gapopen = 10.0, gapextend=0.5 and matrix=EDNAFU LL) .

Protein expression

There is no limitation on the origin of the protein of interest of the invention. Thus, the term protein of interest includes not on ly natu ral or wild-type proteins, but also any mutant variants, fragments, etc. of the protein of interest, as wel l as synthetic protein. Such genetical ly engineered proteins can be prepared as is general ly known in the art, e.g., by site-directed mutagenesis, by PCR (using a PCR fragment containing the desired mutation as one of the primers in the PCR reactions) , or by random mutagenesis.

The microorganism can comprise the gene encoding the protein of interest (i.e., gene of interest) endogenously or the gene of interest can be heterologous to the microbial cel l. Preferably, the gene encoding the protein of interest is heterologous to the host cel l.

The desired protein may be secreted into the liquid fraction of the fermentation broth or may remain inside the microbial cel ls. Preferably, the fermentation product is secreted by the microorganism into the fermentation broth. Secretion of the protein of interest into the fermentation medium al lows for separation of the protein of interest from the fermentation broth. For secretion of the protein of interest into the fermentation mediu m the nucleic acid construct used for expressing the protein of interest com prises a polynucleotide encoding for a signal peptide that directs secretion of the protein of interest into the fermentation medium. Various signal peptides are known in the art. Preferred signal peptides are selected from the grou p consisting of the signal peptide of the AprE protein from Bacillus subti/is or the signal peptide from the YvcE protein from Bacillus subiti/is.

Specific em bodiments

The fol lowing shows a list of specific em bodiments of the invention:

I n one embodiment, the present invention relates to a method of recovering a protein of interest from a fermentation broth comprising the steps of

a) adding CaCI ₂ to the fermentation broth or a fraction thereof comprising the

protein of interest, and

b) adjusting the pH of the fermentation broth to more than pH 11, and

c) separating the protein of interest from im pu rities and/or biomass. I n one em bodiment, the present invention relates to a method of recovering a protein of interest from a fermentation broth comprising the steps of

a) adding MgCI ₂ to the fermentation broth or a fraction thereof comprising the protein of interest, and

b) adjusting the pH of the fermentation broth to more than pH 11, and

c) separating the protein of interest from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering a protease from a fermentation broth comprising the steps of

a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof com prising the protease, and

b) adjusting the pH of the fermentation broth to more than pH 11, and

c) separating the protease from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an amylase from a fermentation broth comprising the steps of

a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof com prising the amylase, and

b) adjusting the pH of the fermentation broth to more than pH 11, and

c) separating the amylase from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an a-amylase from a fermentation broth comprising the steps of

a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof com prising the a-amylase, and

b) adjusting the pH of the fermentation broth to more than pH 11, and

c) separating the a-amylase any impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an a-amylase from a fermentation broth or a fraction thereof com prising the steps of

a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof com prising the protein of interest, and

b) adjusting the pH of the fermentation broth or a fraction thereof to more than pH 11, and

c) separating the protein of interest from impu rities and/or biomass,

wherein the fermentation broth or the fraction thereof prior to the addition of the divalent cation com prises phosphate, preferably, wherein the phosphate in the fermentation broth or the fraction thereof does not exceed 10 m mol after the addition of the salt of the divalent cation.

I n one em bodiment, the present invention relates to a method of recovering a protein of interest from a fermentation broth com prising the steps of

a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof com prising the protein of interest, and

b) adjusting the pH of the fermentation broth to pH 11.5, and

c) separating the protein of interest from im pu rities and/or biomass. I n one embodiment, the present invention relates to a method of recovering a protein of interest from a fermentation broth com prising the steps of

a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof com prising the protein of interest, and

b) adjusting the pH of the fermentation broth to pH 12, and

c) separating the protein of interest from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering a protein of interest from a fermentation broth com prising the steps of

a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof com prising the protein of interest, and

b) adjusting the pH of the fermentation broth to pH 12.5, and

c) separating the protein of interest from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering a protease from a fermentation broth comprising the steps of

a) adding CaCI ₂ to the fermentation broth or a fraction thereof comprising the protease, and

b) adjusting the pH of the fermentation broth to more than pH 11, and

c) separating the protease from impu rities and/or biomass.

I n one embodiment, the present invention relates to a method of recovering an amylase from a fermentation broth comprising the steps of

a) adding CaCI ₂ to the fermentation broth or a fraction thereof comprising the

amylase, and

b) adjusting the pH of the fermentation broth to more than pH 11, and

c) separating the amylase from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an a-amylase from a fermentation broth comprising the steps of

a) adding CaCI ₂ to the fermentation broth or a fraction thereof comprising the a- amylase, and

b) adjusting the pH of the fermentation broth to more than pH 11, and

c) separating the a-amylase from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering a protease from a fermentation broth comprising the steps of

a) adding MgCI ₂ to the fermentation broth or a fraction thereof comprising the protease, and

b) adjusting the pH of the fermentation broth to more than pH 11, and

c) separating the protease from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an amylase from a fermentation broth comprising the steps of a) adding MgCI ₂ to the fermentation broth or a fraction thereof comprising the amylase, and

b) adjusting the pH of the fermentation broth to more than pH 11, and c) separating the amylase from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an a-amylase from a fermentation broth comprising the steps of

a) adding MgCI ₂ to the fermentation broth or a fraction thereof comprising the a- amylase, and

b) adjusting the pH of the fermentation broth to more than pH 11, and c) separating the a-amylase from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering a protein of interest from a fermentation broth com prising the steps of

a) adding CaCI ₂ to the fermentation broth or a fraction thereof comprising the protein of interest, and

b) adjusting the pH of the fermentation broth to pH 11.5, and

c) separating the protein of interest from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering a protein of interest from a fermentation broth com prising the steps of

a) adding CaCI ₂ to the fermentation broth or a fraction thereof comprising the protein of interest, and

b) adjusting the pH of the fermentation broth to pH 12, and

c) separating the protein of interest from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering a protein of interest from a fermentation broth com prising the steps of

a) adding CaCI ₂ to the fermentation broth or a fraction thereof comprising the protein of interest, and

b) adjusting the pH of the fermentation broth to pH 12.5, and

c) separating the protein of interest from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering a protein of interest from a fermentation broth com prising the steps of

a) adding MgCI ₂ to the fermentation broth or a fraction thereof comprising the protein of interest, and

b) adjusting the pH of the fermentation broth to pH 11.5, and

c) separating the protein of interest from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering a protein of interest from a fermentation broth com prising the steps of

a) adding MgCI ₂ to the fermentation broth or a fraction thereof comprising the protein of interest, and

b) adjusting the pH of the fermentation broth to pH 12, and

c) separating the protein of interest from im pu rities and/or biomass. I n one em bodiment, the present invention relates to a method of recovering a protein of interest from a fermentation broth com prising the steps of

a) adding MgCI ₂ to the fermentation broth or a fraction thereof comprising the protein of interest, and

b) adjusting the pH of the fermentation broth to pH 12.5, and

c) separating the protein of interest from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering a protease from a fermentation broth comprising the steps of

a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof com prising the protease, and

b) adjusting the pH of the fermentation broth to pH 11.5, and

c) separating the protease from impu rities and/or biomass.

I n one embodiment, the present invention relates to a method of recovering a protease from a fermentation broth comprising the steps of

a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof com prising the protease, and

b) adjusting the pH of the fermentation broth to pH 12, and

c) separating the protease from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering a protease from a fermentation broth comprising the steps of

a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof com prising the protease, and

b) adjusting the pH of the fermentation broth to pH 12.5, and

c) separating the protease from impu rities and/or biomass.

I n one embodiment, the present invention relates to a method of recovering a protease from a fermentation broth comprising the steps of

a) adding CaCI ₂ to the fermentation broth or a fraction thereof comprising the

protease, and

b) adjusting the pH of the fermentation broth to pH 11.5, and

c) separating the protease from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering a protease from a fermentation broth com prising the steps of

a) adding CaCI ₂ to the fermentation broth or a fraction thereof comprising the protease, and

b) adjusting the pH of the fermentation broth to pH 12, and

c) separating the protease from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering a protease from a fermentation broth comprising the steps of

a) adding CaCI ₂ to the fermentation broth or a fraction thereof comprising the protease, and b) adjusting the pH of the fermentation broth to pH 12.5, and

c) separating the protease from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering a protease from a fermentation broth comprising the steps of

a) adding MgCI ₂ to the fermentation broth or a fraction thereof comprising the protease, and

b) adjusting the pH of the fermentation broth to pH 11.5, and

c) separating the protease from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering a protease from a fermentation broth comprising the steps of

a) adding MgCI ₂ to the fermentation broth or a fraction thereof comprising the protease, and

b) adjusting the pH of the fermentation broth to pH 12, and

c) separating the protease from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering a protease from a fermentation broth comprising the steps of

a) adding MgCI ₂ to the fermentation broth or a fraction thereof comprising the protease, and

b) adjusting the pH of the fermentation broth to pH 12.5, and

c) separating the protease from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an amylase from a fermentation broth comprising the steps of

a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof com prising the amylase, and

b) adjusting the pH of the fermentation broth to pH 11.5, and

c) separating the amylase from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an amylase from a fermentation broth comprising the steps of

a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof com prising the amylase, and

b) adjusting the pH of the fermentation broth to pH 12, and

c) separating the amylase from im pu rities and/or biomass.

I n one embodiment, the present invention relates to a method of recovering an amylase from a fermentation broth comprising the steps of

a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof com prising the amylase, and

b) adjusting the pH of the fermentation broth to pH 12.5, and

c) separating the amylase from im pu rities and/or biomass. I n one em bodiment, the present invention relates to a method of recovering an amylase from a fermentation broth comprising the steps of

a) adding CaCI ₂ to the fermentation broth or a fraction thereof comprising the amylase, and

b) adjusting the pH of the fermentation broth to pH 11.5, and

c) separating the amylase from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an amylase from a fermentation broth comprising the steps of

a) adding CaCI ₂ to the fermentation broth or a fraction thereof comprising the amylase, and

b) adjusting the pH of the fermentation broth to pH 12, and

c) separating the amylase from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an amylase from a fermentation broth comprising the steps of

a) adding CaCI ₂ to the fermentation broth or a fraction thereof comprising the amylase, and

b) adjusting the pH of the fermentation broth to pH 12.5, and

c) separating the amylase from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an amylase from a fermentation broth comprising the steps of

a) adding MgCI ₂ to the fermentation broth or a fraction thereof comprising the amylase, and

b) adjusting the pH of the fermentation broth to pH 11.5, and

c) separating the amylase from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an amylase from a fermentation broth comprising the steps of

a) adding MgCI ₂ to the fermentation broth or a fraction thereof com prising the amylase, and

b) adjusting the pH of the fermentation broth to pH 12, and

c) separating the amylase from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an amylase from a fermentation broth com prising the steps of

a) adding MgCI ₂ to the fermentation broth or a fraction thereof comprising the amylase, and

b) adjusting the pH of the fermentation broth to pH 12.5, and

c) separating the amylase from im pu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an a-amylase from a fermentation broth comprising the steps of

a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof com prising the a-amylase, and

b) adjusting the pH of the fermentation broth to pH 11.5, and c) separating the a-amylase from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an a-amylase from a fermentation broth comprising the steps of

a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof com prising the a-amylase, and

b) adjusting the pH of the fermentation broth to pH 12, and

c) separating the a-amylase from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an a-amylase from a fermentation broth comprising the steps of

a) adding a salt of a divalent cation to the fermentation broth or a fraction thereof com prising the a-amylase, and

b) adjusting the pH of the fermentation broth to pH 12.5, and

c) separating the a-amylase from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an a-amylase from a fermentation broth comprising the steps of

a) adding CaCI ₂ to the fermentation broth or a fraction thereof comprising the a- amylase, and

b) adjusting the pH of the fermentation broth to pH 11.5, and

c) separating the a-amylase from ay im purities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an a-amylase from a fermentation broth comprising the steps of

a) adding CaCI ₂ to the fermentation broth or a fraction thereof comprising the a- amylase, and

b) adjusting the pH of the fermentation broth to pH 12, and

c) separating the a-amylase from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an a-amylase from a fermentation broth comprising the steps of

a) adding CaCI ₂ to the fermentation broth or a fraction thereof comprising the a- amylase, and

b) adjusting the pH of the fermentation broth to pH 12.5, and

c) separating the a-amylase from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an a-amylase from a fermentation broth comprising the steps of

a) adding MgCI ₂ to the fermentation broth or a fraction thereof comprising the a- amylase, and

b) adjusting the pH of the fermentation broth to pH 11.5, and

c) separating the a-amylase from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an a-amylase from a fermentation broth comprising the steps of a) adding MgCI ₂ to the fermentation broth or a fraction thereof comprising the a- amylase, and

b) adjusting the pH of the fermentation broth to pH 12, and

c) separating the a-amylase from impu rities and/or biomass.

I n one em bodiment, the present invention relates to a method of recovering an a-amylase from a fermentation broth comprising the steps of

a) adding MgCI ₂ to the fermentation broth or a fraction thereof comprising the a- amylase, and

b) adjusting the pH of the fermentation broth to pH 12.5, and

c) separating the a-amylase from impu rities and/or biomass.

The invention is fu rther il lustrated in the fol lowing exam ples which are not intended to be in any way limiting to the scope of the invention as claimed.

Examples

The fol lowing examples on ly serve to il lustrate the invention. The nu merous possible variations that are obvious to a person skil led in the art also fal l within the scope of the invention.

U nless otherwise stated the fol lowing experiments have been performed by applying standard equipment, methods, chemicals, and biochemicals as used in genetic engineering and fermentative production of chemical compou nds by cultivation of microorganisms. See also Sam brook et al. (Molecu lar Cloning: A Laboratory Manual. 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) and Ch miel et al. (Bioprocesstechnik 1. EinfO h ru ng in die Bioverfah renstech nik, Gustav Fischer Verlag, Stuttgart, 1991) .

The fermentation broths for the exam ples below (Exam ples 1-3) were obtained by cu lturing Bacillus Hcheniformis cel ls com prising a gene coding for an amylase which is a variant of the SP722 amylase disclosed in WO 96/23873. Bacillus Hcheniformis cel ls were cultivated in a fermentation process using a chemical ly defined fermentation medium providing the com ponents listed in Table 1 and Table 2.

Table 1: Macroelements provided during the cou rse of the fermentation process Compound Formula Concentration [g/L initial volume]

Citric acid C ₆ H ₈ 0 ₇ 3.0

Calcium sulfate CaS0 ₄ 0.7

Monopotassiu m phosphate KH ₂ P0 ₄ 25

Magnesiu m su lfate MgS0 ₄ *7H ₂ 0 4.8

Sodiu m hydroxide NaOH 4.0

Am monia N H, 1.3

Table 2: Trace elements provided du ring the cou rse of the fermentation process

Trace element Symbol Concentration [mM]

Manganese M n 24

Zinc Zn 17

Copper Cu 32

Cobalt Co 1

Nickel Ni 2

Molybdenu m Mo 0.2

I ron Fe 38

A solution containing 50% glucose was used as feed solution. pH was adjusted du ring fermentation using ammonia. At the desired product titer the fermentation was terminated, and the product amylase was present in both soluble and crystal line form as confirmed by visual inspection using a microscope. At the end of fermentation, the phosphate

concentration was about 3 g/L.

Example 1

The fol lowing exam ple shows that a pH level of more than 11.0 is needed to dissolve (solu bilize) a su bstantial fraction of the present amylase crystals in the fermentation broth. The fermentation broth was adjusted to pH levels 11.0, 11.5 and 12.0 by adding diluted (10% (w/v)) NaOH solution under stirring. As soon as the desired pH was reached, optical density samples of the 0 min time point were taken, and the su pernatant was further incu bated up to 120 min u nder stirring. Further samples were taken at several time points during the incu bation period. To determine the optical density at 700 nm (OD700) , the samples were diluted 1:100 with water and then measu red in a photometer at 700 n m.

The OD700 values decreased du ring the first 15 min of incubation to a plateau value (Figu re 1). The decrease in OD700 reflects crystal dissolution. Figu re 1 shows that the degree of crystal dissolution (solubilization) depends on the pH level of the solution with higher pH levels resu lting in better crystal dissolution. I m portantly, a pH level of more than 11.0 is needed to dissolve an acceptable fraction of the amylase crystals for further recovery and purification operations.

Example 2 The following example shows that without prior addition of CaCI ₂ substantial loss of enzyme activity in the soluble fraction occurs at pH levels above 11.

The fermentation broth was centrifuged in a laboratory centrifuge at 10000 g for 10 min.

The supernatant was adjusted to pH levels 11.0, 11.5 and 12.0 by adding diluted (10%

(w/v)) NaOH solution under stirring. As soon as the desired pH was reached, enzyme activity samples of the 0 min time point were taken, and the supernatant was further incubated up to 120 min under stirring. Further samples were taken at several time points during the incubation period. To determine the remaining enzyme activity, the samples were diluted directly into analysis buffer (50% MPG, MOPS, pH=7), centrifuged and the supernatant was analyzed using an amylase activity assay (Lorentz K. et al. (2000), din. Chem., 46/5: 644 - 649).

In Figure 2 the remaining enzyme activity of the amylase containing supernatant relative to the 0 min value of every sample is shown. The pH 11 sample showed a decrease of activity of 1 percentage points over 120 min. The pH 11.5 sample showed a decrease of activity of 9 percentage points over 120 min, wherein the highest decrease was observed in the first 30 min. The pH 12.0 sample lost complete activity in the first 30 min.

Example 3

The following example shows that addition of CaCI ₂ prior to adjusting the pH level above 11.0 prevents substantial loss of enzyme activity in the soluble fraction.

The fermentation broth was centrifuged in a laboratory centrifuge at 10000 g for 10 min. Prior to adjusting the pH, 7.5 g/L CaCI ₂ was added to the supernatant under stirring. The supernatant was then adjusted to pH levels 11.0, 11.5 and 12.0 by adding diluted (10% (w/v)) NaOH solution under stirring. As soon as the desired pH was reached, activity samples of the 0 min time point were taken, and the supernatant was further incubated up to 120 min under stirring. Further samples were taken at several time points during the incubation period. To determine the remaining enzyme activity, the samples were diluted directly into analysis buffer (50% M PG, MOPS, pH=7), centrifuged and the supernatant was analyzed using an amylase activity assay (Lorentz K. et al. (2000), din. Chem., 46/5: 644 - 649).

In Figure 3 the remaining enzyme activity of the amylase containing supernatant relative to the 0 min value of every sample is shown. The pH 11.0 and pH 11.5 samples showed almost no activity decrease over 90 min. The pH 12.0 sample lost about 14 percentage points of activity over 90 min. In comparison to the results in Example 2 it shows that the addition of CaCI ₂ prevents enzyme activity loss at pH 11.5 almost completely and reduced enzyme activity loss at pH 12.0 significantly.